



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No. 02-793-C)**

### **Application of:**

Varghese John et al.

**Serial No.: 10/658,959**

**Filing Date: September 10, 2003**

**For: Acetyl 2-Hydroxy-1,3-Diaminoalkanes**

**Examiner: TBA**

**Group Art Unit: 1625**

## TRANSMITTAL LETTER

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Transmittal Letter in duplicate
  - b) Supplemental Information Disclosure Statement (2 Sheets)
  - c) Supplemental Information Disclosure Statement Form PTO-1449 (1 sheet)
  - d) 1 cited reference
  - e) Return Receipt Postcard.
2. With respect to fees:
  - a) No Fees is required.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450 on this 19 day of January, 2005.

Respectfully submitted,

*Brad Crawford*  
Bradley W. Crawford  
Registration No. 50,494





PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. MBHB 02-793-C)

IN THE APPLICATION OF:	)		
	)		
John, et al.	)		
	)		
Serial No. 10/658,959	)	Examiner:	To Be Assigned
	)		
Filed: September 10, 2003	)	Group Art Unit:	1625
	)		
Title Acetyl 2-hydroxy-1,3-diaminoalkanes	)	Confirmation No.:	3516
	)		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.



### **Other Documents**

1. Kempf, et al., "Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol," *J. Med. Chem.*, 36, 320-330 (1993)


In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff**

Date: January 19, 2005

By:

  
**Bradley W. Crawford**  
**Registration No. 50,494**



FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office


Atty. Docket No.

02-793-C

Serial No.

10/658,959

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use several sheets if necessary)



Applicant:

John, et al.

Filing Date:

09-10-03

Group:

1625

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

			Kempf, et al., "Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol," <i>J. Med. Chem.</i> , 36, 320-330 (1993)
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.